About Hemosonics
Hemosonics is a company based in Charlottesville (United States) founded in 2004 was acquired by Diagnostica Stago in May 2017. Hemosonics has raised $24.92 million across 9 funding rounds from investors including HHS, Diagnostica Stago and U.S. Air Force. Hemosonics has completed 1 acquisition, including Diagnostica Stago. Hemosonics offers products and services including Quantra® Hemostasis Analyzer, QPlus® Cartridge, QStat® Cartridge, Quantra® Quality Control Kits, and Qualiris EQA Proficiency Program. Hemosonics operates in a competitive market with competitors including Perosphere Technologies, Atantares, Stasys, HemoSense and ClotChip, among others.
- Headquarter Charlottesville, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Hemosonics, Llc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$24.92 M (USD)
in 9 rounds
-
Latest Funding Round
$15 M (USD), Series B
Feb 14, 2017
-
Investors
HHS
& 3 more
-
Employee Count
Not available
- Investments & Acquisitions
-
Acquired by
Diagnostica Stago
(May 30, 2017)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Hemosonics
Hemosonics offers a comprehensive portfolio of products and services, including Quantra® Hemostasis Analyzer, QPlus® Cartridge, QStat® Cartridge, Quantra® Quality Control Kits, and Qualiris EQA Proficiency Program.
Device for viscoelastic testing of blood coagulation in surgical settings.
Cartridge for coagulation evaluations in point-of-care applications.
Cartridge to assess hypocoagulable and hypercoagulable conditions in trauma.
Kits for ensuring accuracy in hemostasis testing procedures.
Program for external quality assessment of hemostasis testing.
People of Hemosonics
Unlock access to complete
Funding Insights of Hemosonics
Hemosonics has successfully raised a total of $24.92M across 9 strategic funding rounds. The most recent funding activity was a Series B round of $15 million completed in February 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Hemosonics
Hemosonics has secured backing from 4 investors, including institutional investors. Prominent investors backing the company include HHS, Diagnostica Stago and U.S. Air Force.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Aerial defense and operations are conducted for national security.
|
Locked | Locked | Locked | |
|
Research on heart, lung, blood, and sleep disorders is conducted.
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for Hemosonics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Hemosonics
Hemosonics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Diagnostica Stago.
Investment portfolio details for Hemosonics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
A portfolio of hemostasis and coagulation diagnostic products is manufactured.
|
Locked | Locked | 1998 | Locked |
Complete acquisition details for Hemosonics
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Hemosonics
Detailed financials for Hemosonics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Hemosonics Comparisons
Peer comparison for Hemosonics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Hemosonics
Hemosonics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Perosphere Technologies, Atantares, Stasys, HemoSense and ClotChip, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Point-of-care coagulation diagnostics and drug delivery systems are developed.
|
|
| Locked | Locked | Locked |
Developer of precision medicines & smart diagnostic devices by fusing biochip and AI technologies
|
|
| Locked | Locked | Locked |
Provider of POC device for analyzing blood clotting disorders and platelet dysfunction
|
|
| Locked | Locked | Locked |
Rapid Point-of-Care Coagulation analyzer
|
|
| Locked | Locked | Locked |
Portable tests for blood coagulation analysis are developed.
|
Detailed competitors of Hemosonics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Hemosonics
Complete news archive for Hemosonics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Hemosonics
Hemosonics was founded in 2004 and raised its 1st funding round 6 years after it was founded.
Hemosonics is headquartered in Charlottesville, United States. It is registered at Charlottesville, Virginia, United States.
Hemosonics is a funded company, having raised a total of $24.92M across 9 funding rounds to date.
HemoSonics is a privately held medical device company founded to develop and bring to market innovative in vitro diagnostics to characterize hemostasis in a variety of clinical settings. These systems employ a patented approach named sonorheometry (SR). The products combine a flexible test device with targeted disposable test chambers to diagnose specific defects of hemostasis and inform appropriate therapy. The company claims that this approach makes their system easier to operate and interpret than existing products. Potential clinical applications include trauma, cardiovascular procedures, organ transplantation, orthopedic surgery, neurological surgery, and labor and delivery among others. This technology has undergone clinical and laboratory testing supported by a series of academic and business grants from the National Institutes of Health, the Wallace H. Coulter Foundation for Translational Research, the Office of Naval Research, and private investors. Sonorheometry has been demonstrated in a series of peer-reviewed scientific publications and has undergone both laboratory and clinical evaluation. Standalone prototypes are undergoing further clinical and laboratory evaluation. HemoSonics LLC is developing a POC instrument, the Global Hemostasis Analyzer (GHA) that can quantify the function of the four hemostatic components, enabling correct selection of treatment. The Quantra is based on sonorheometry (SR), a novel technology able to assess not only time to clot (dependent upon the plasma coagulation factors) but also clot formation rate (dependent upon fibrinogen), clot stiffness (dependent upon fibrinogen and platelets), and time to lysis (dependent upon clot-dissolving proteins).
Hemosonics's top competitors include Perosphere Technologies, Atantares and Stasys.
Hemosonics offers Quantra® Hemostasis Analyzer, QPlus® Cartridge, QStat® Cartridge, Quantra® Quality Control Kits, and Qualiris EQA Proficiency Program.
Hemosonics has made 1 acquisition, including Diagnostica Stago.
Hemosonics has 4 investors. Key investors include HHS, Diagnostica Stago, U.S. Air Force, and National Heart, Lung, and Blood Institute.